Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SerpinPC for Severe Hemophilia A or B (PRESent-2)
NCT05789524Phase 2Terminated
- Sponsor
- ApcinteX Ltd.
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of serpinpc in hemophilia A and hemophilia B (HB) (5 arms), sponsored by ApcinteX Ltd. Primary endpoint: Annualized Bleeding Rate for Treated Bleeds at 24 weeks. Started Jul 2023; status: terminated.
02
Drugs
serpinpc
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05789524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789524.